Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement decay-accelerating factor (DAF)
- Target
- DAF
- Molecular classification
- Membrane-bound glycoprotein, Complement control protein (CCP), GPI-anchored protein
01
Overview
Complement decay-accelerating factor (DAF), also known as CD55, is a membrane-bound glycoprotein that regulates the complement system. It protects host cells from autologous complement-mediated damage by accelerating the decay/dissociation of C3 and C5 convertases in both the classical and alternative pathways. DAF is broadly expressed on hematopoietic and non-hematopoietic cells and is implicated in various diseases, including paroxysmal nocturnal hemoglobinuria (PNH). It is a potential therapeutic target for diseases involving excessive complement activation.
- Other names
- CD55Cromer blood group antigen
02
Mechanism of action
Accelerates the decay/dissociation of C3 and C5 convertases in both classical and alternative complement pathways by binding to C4b or C3b, destabilizing preformed convertases and preventing further amplification and membrane attack complex formation.
03
Biological functions
Immune response regulationComplement system regulationInhibition of complement convertase activityProtection of host cells from complement-mediated damageReceptor for certain viruses/microorganismsLigand for CD97 receptorRegulation of natural killer cell function
04
Disease associations
Paroxysmal nocturnal hemoglobinuria (PNH)Lung fibrosisRenal nephritis/fibrosisRetinal degenerationTumorigenesis
05
Safety considerations
Potential for inhibiting anti-tumor immunity by protecting tumor cells from complement-mediated lysisPotential for facilitating viral/microbial infection due to receptor function
Beyond the preview
Go deeper on Complement decay-accelerating factor (DAF).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Complement decay-accelerating factor (DAF).